Veristat, LLC
United States
39 articles about Veristat, LLC
-
Veristat Taps Accomplished Industry Leaders to Support Growth and Innovation
5/23/2023
Veristat, a scientific-minded global clinical research organization and regulatory consultancy, shared the addition of three seasoned leaders to Veristat’s Executive team.
-
Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine
4/25/2023
Veristat congratulated HIPRA for marketing authorization by the European Medicines Agency and European Commission of BIMERVAX®, a bivalent adjuvanted vaccine based on the Beta and Alpha variants of SARS-CoV-2 and indicated as a booster dose for people over 16 years of age.
-
Veristat Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed to Treat Rare Diseases
2/14/2023
Veristat, a scientific-minded global clinical research organization (CRO), announced today that the Company supported clients in preparing marketing applications for eight therapies that received regulatory approval in 2022.
-
ValGenesis and Verista Announce Strategic Global Partnership to Provide Manufacturing Intelligence and Digital Validation Services for Life Sciences Companies
12/19/2022
ValGenesis and Verista have announced a strategic global partnership to deliver precise manufacturing intelligence and validation services for life sciences companies leveraging ValGenesis' market-leading Validation Lifecycle Management System® and Verista's expert domain and validation knowledge.
-
Veristat Joins Decentralized Trials & Research Alliance (DTRA) to Improve the Patient Experience
10/13/2022
Veristat announced that it has joined an alliance of over 120 life sciences and healthcare organizations whose mission is to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
-
Veristat Expands its Expertise and Scale across Biopharma and Medtech
3/7/2022
Veristat, a scientific-minded global clinical research organization, announced the expansion and strengthening of its service capabilities by acquiring SFL.
-
Veristat Announces New Investment Partner—WindRose Health Investors
4/7/2021
Veristat , a scientific-minded, global clinical research organization (CRO), announced today that it transferred its majority ownership from Variance Development Partners to WindRose Health Investors (WindRose). WindRose invests exclusively in healthcare companies and has extensive experience across the healthcare services landscape
-
Veristat Expands Global Service Capability in Biometrics with Acquisition of SQN Clinical
2/25/2021
Builds on a shared pedigree of data management, statistics, and programming excellence across all phases of clinical trials
-
Veristat Launches Business Operations in Spain and Names Dr. Montserrat Barceló to Vice President, Europe
1/11/2021
Veristat, a scientific-minded global clinical research organization, announced the launch of business operations in Spain and the appointment of Montserrat Barceló Riera, M.D. as Vice President, Europe.
-
Veristat Named Top Patient Recruitment Company 2020 by Pharma Tech Outlook
12/7/2020
Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook.
-
Veristat Announces Global Cell and Gene Therapy Center of Excellence
10/22/2020
Accelerating cell and gene therapy opportunities for patients by advancing access to knowledge and leveraging experience for sponsors to increase program success.
-
Introducing VERISTA: An Industry-Leading Solutions Provider to Pharma & Life Sciences, Food & Beverage, Manufacturing Industries
10/21/2020
Verista, an industry-leading solutions provider to some of the world's most recognizable brands, officially unveiled its new name , the result of unifying Clarke Solutions, Covex LLC and Acquire Automation.
-
Veristat Enhances Patient-Centricity Offering by Delivering Clinical Trials Directly to Patients
9/30/2020
Veristat , a scientific-minded global clinical research organization (CRO), announced today the launch of a virtual clinical trial solution that is flexible and customizable so that patient interactions can be conducted at the clinical site, remotely at-home, or through a hybrid combination of both strategies. “The time for virtual clinical trial ado
-
Veristat Strengthens Its Regulatory Expertise with the Acquisition of Catalyst Regulatory Services
12/16/2019
Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors Along the Pathway to Market Approval
-
Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals
1/6/2019
Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding
-
Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients
11/5/2018
Veristat announced today that it has partnered with Triumph Research Intelligence (TRI), a global leader providing technology and solutions for centralized and risk-based monitoring (RBM) to improve clinical trial quality and compliance.
-
Veristat Strengthens Clinical Operations Capabilities with The Acquisition of Topstone Research
10/1/2018
Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma
-
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™ (patisiran)
8/20/2018
Continues Collaboration to Provide Regulatory Submission Support for Additional Patisiran Submissions
-
Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year
8/15/2018
Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That Reach Regulatory Approval.
-
Veristat And AOBiome Establish A Preferred Partnership To Support Ongoing & Impending Clinical Programs
6/19/2017